Thursday, July 13, 2017 10:59:25 AM
By Tom Angell | July 12, 2017
First, Congressman Matt Gaetz (R-FL) offered an amendment that would have expanded research on marijuana’s potential medical benefits.
Due to its current status as a Schedule I drug, scientists who wish to study cannabis must overcome extra procedural hurdles that don’t exist for research on other substances.
“It seems ludicrous to me that any notion of conservative limited government would put the federal government between someone who was ailing in pain and something that could potentially help them,” said Gaetz, who is also cosponsoring a separate standalone bill to move marijuana to Schedule III. (cont'd)
https://www.massroots.com/news/cannabis-strains-hardest-to-grow?is=1
Recent CEAD News
- CEA Industries Inc. Reports Fourth Quarter and Full Year 2023 Results • GlobeNewswire Inc. • 03/28/2024 08:10:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:05:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:04:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:04:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 09:04:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2023 10:19:04 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 11/30/2023 09:00:22 PM
- CEA Industries Inc. Reports Third Quarter 2023 Results • GlobeNewswire Inc. • 11/14/2023 09:15:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:00:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 09:27:27 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/26/2023 08:26:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/13/2023 03:01:38 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 10/11/2023 06:45:32 PM
- CEA Industries Inc. Reports Second Quarter 2023 Results and Initiates Review of Strategic Alternatives • GlobeNewswire Inc. • 08/14/2023 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:00:46 PM
- CEA Industries Inc. to Hold Second Quarter 2023 Conference Call on August 14 at 4:15 p.m. ET • GlobeNewswire Inc. • 08/07/2023 12:00:00 PM
- CEA Industries Inc. Reports First Quarter 2023 Results • GlobeNewswire Inc. • 05/15/2023 08:05:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM